978.F ADAGENE INC. SP.ADR

Healthcare Biotechnology Frankfurt Exchange
1.78 EUR
Close of Nov 11, 2026
1.31 4.04
Market cap
EUR 120M
P/E
-
P/B
1.46x
ROE
-49.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 978.F undervalued?

Graham number

The Graham number of ADAGENE INC. SP.ADR cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ADAGENE INC. SP.ADR fundamental analysis

No fundamental analysis for ADAGENE INC. SP.ADR yet.

ADAGENE INC. SP.ADR stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ADAGENE INC. SP.ADR

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials …

Full company profile